Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2019 | Side effects of CAR T-cell therapy

Michael Schmitt • 10 Apr 2019
EBMT 2019
Lymphoma Non-Hodgkin Lymphoma CAR-T

Michael Schmitt, MHBA, of University Hospital Heidelberg, Germany, explores the side effects of CD19 CAR T-cell therapy in patients with acute- and non-Hodgkin lymphoma. Prof. Schmitt was speaking at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2019, held in Frankfurt, Germany.

More from Michael Schmitt

Pros and cons of autologous and allogeneic CAR-Ts
2:46
Pros and cons of autologous and allogeneic CAR-Ts
Michael Schmitt • 7 Feb 2022
Exciting developments in the CAR space: novel target antigens, CAR-NKs & switchable CAR-Ts
4:25
Exciting developments in the CAR space: novel target antigens, CAR-NKs & switchable CAR-Ts
Michael Schmitt • 7 Feb 2022
Preparing for the commercialization of CAR-T products
4:17
Preparing for the commercialization of CAR-T products
Michael Schmitt • 7 Feb 2022
CD19 CAR T-cell therapy for lymphoma
2:55
CD19 CAR T-cell therapy for lymphoma
Michael Schmitt • 26 Apr 2019

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Michael Schmitt • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Michael Schmitt • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Michael Schmitt • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Michael Schmitt • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals